What other allegations is Bafin investigating?

In addition to the incorrect accounting of a receivable, the authority has indications that transactions with a related party were insufficiently explained.

On what legal basis is Bafin acting?

Bafin is acting on the basis of the German Securities Trading Act (§ 107 (1) sentence 1 WpHG) and is obliged to announce such cause-based reviews.

Bafin reviews Dermapharm's 2025 consolidated financial

Q: What is the specific reason for Bafin's review of Dermapharm?

Bafin cites as the reason that the accounting treatment of a receivable, including interest claims recognized thereon in the amount of 63.2 million euros, may have been incorrect.

Frankfurt am Main, July 17, 2026

The Federal Financial Supervisory Authority (Bafin) has initiated a review of the consolidated financial statements and the associated management report of Dermapharm Holding SE for fiscal year 2025.

The review concerns the accounting treatment of a receivable, including interest claims recognized thereon in the amount of 63.2 million euros. Bafin stated that this may have been accounted for incorrectly.

Reason for the review

According to its own announcement, the authority also has concrete indications that Dermapharm Holding SE violated accounting regulations.

A further audit point is transactions with a related party, which, in Bafin's view, were insufficiently explained.

Bafin initiates review of Dermapharm's 2025 consolidated financial statements

Reason for the review

Legal basis

Focus of the review

Questions & Answers